Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Daily News

Proximity to Physical Activity Facilities May Play Role in Body Fat Levels

Michael O'Riordan

December 13, 2017

News Daily News

Surviving CVD: Obesity Offers No Protection for Those With New Onset Cardiac Events

Michael O'Riordan

December 07, 2017

News Daily News

Diabetes Remission Possible With Significant Weight Loss: DiRECT

Michael O'Riordan

December 05, 2017

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Daily News

Statins and Diabetes: Causal Link Reinforced in New Analysis

Michael O'Riordan

October 25, 2017

News Daily News

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Michael O'Riordan

October 24, 2017

News Daily News

Patients in PCI Trials Vary Around the World, With Women Still Underrepresented

Michael O'Riordan

September 15, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

News Daily News

Black Men Have Twofold Higher Risk of Dying From First CHD Event

Michael O'Riordan

July 10, 2017

News Daily News

Higher BMI Linked to Increased Risk of CHD, Hypertension, and Diabetes

Michael O'Riordan

July 06, 2017

News Daily News

Growing Gap in CVD Risk Factor Control Between Rich and Poor

Michael O'Riordan

June 08, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Conference News EuroPCR 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Michael O'Riordan

May 18, 2017

News Daily News

‘Sizeable’ Segment of Public, Even When at High CVD Risk, Feels No Need to Improve Health

Michael O'Riordan

May 04, 2017

News

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Michael O'Riordan

April 13, 2017

News Daily News

Trans Fat Ban Led to Tangible CVD Benefits, New York State Analysis Shows

Michael O'Riordan

April 12, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Advertisement

Proximity to Physical Activity Facilities May Play Role in Body Fat Levels

Surviving CVD: Obesity Offers No Protection for Those With New Onset Cardiac Events

Diabetes Remission Possible With Significant Weight Loss: DiRECT

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Statins and Diabetes: Causal Link Reinforced in New Analysis

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Patients in PCI Trials Vary Around the World, With Women Still Underrepresented

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Black Men Have Twofold Higher Risk of Dying From First CHD Event

Higher BMI Linked to Increased Risk of CHD, Hypertension, and Diabetes

Growing Gap in CVD Risk Factor Control Between Rich and Poor

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

‘Sizeable’ Segment of Public, Even When at High CVD Risk, Feels No Need to Improve Health

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Trans Fat Ban Led to Tangible CVD Benefits, New York State Analysis Shows

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content